Moderna Profit Margin

Moderna (MRNA) currently reports a profit margin of -141.43% as of June 2026. That compares with -94.62% in the prior-year period — down 49.5% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Moderna's profit margin history and peer comparisons.

Moderna's profit margin decreased from -94.62% to -141.43% — a 49.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Moderna's profit margin of -141.43% is lower than the Healthcare sector average of 15.29%. That is roughly 1024.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Moderna's current -141.43% should be judged against Healthcare norms (sector average: 15.29%) and against MRNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -141.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Moderna, and consider following MRNA for alerts when major investors trade the stock.